GlobeNewswire·Nov 5, 2026, 7:30 AM ET

SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights

Adult and adolescent cohorts in the registrational SAFEGUARD study are fully enrolled and closed for screening, while the pediatric cohort (ages 5–11) is actively enrolling with completion expected in Q4 2026.
The FDA granted Fast Track designation to SAB-142 for the treatment of new-onset Stage 3 Type 1 Diabetes in October 2026.
The company maintains an operational runway through 2028 supported by $205.3 million in cash, cash equivalents, and investment securities as of September 30, 2026.
The Phase 2b SAFEGUARD study aims to enroll approximately 159 patients within 100 days of diagnosis, with topline data anticipated in the second half of 2027.
The Phase 3 PRISE-hATG study expects to dose its first patient in Q4 2026 and is designed to evaluate SAB-142 in patients up to two years post-diagnosis.
Research and development expenses for the quarter ended September 30, 2026, were $18.1 million, while general and administrative expenses were $7.8 million.
The company reported a net loss of $22.3 million for the three months ended September 30, 2026, compared to a net income of $45.4 million in the same period the prior year.
SAB BIO plans to participate in investor events including the UBS Global Biopharma Conference, Jefferies Global Healthcare Conference, 9th Annual Evercore Healthcare Conference, and Citi Global Healthcare Conference in late November and early December 2026.